Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
dyslipidemias/protease
Linket gemmes på udklipsholderen
Side 1 fra 21 resultater
Effect on HIV Medications on EPC Cells
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Metabolic and endocrine perturbations including insulin resistance, diabetes, and dyslipidemia have been of significant concern in human immunodeficiency virus (HIV)-infected individuals. HIV-infected individuals may be at risk of accelerated atherosclerotic cardiovascular disease (CVD) and
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
General objectives:
Evaluate the therapeutic efficacy in Mexican adults with dyslipidemia through the oral route use of L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.
Evaluate the safety of the medicines under study.
Hypothesis:
The combined use
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Cardiovascular disease (CVD) due to atherosclerosis continues to be the leading single cause of death in industrialized countries. High serum lipid levels, and especially high low-density lipoprotein cholesterol (LDL-C) levels, have been demonstrated to strongly and directly correlate with CVD risks
COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV—Infected Patients
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Background: HIV-infected subjects are at high risk of coronary heart disease (CHD) partly in relation with atherogenic dyslipidemia including increased triglycerides (TG) and LDL-cholesterol (LDL-C). Mechanisms of HIV-associated dyslipidemia are complex, involving HIV itself and some antiretrovirals
Atazanavir and Endothelial Function in Older HIV Patients
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The mortality induced by HIV has dropped significantly due to effective antiretroviral therapy. Epidemiological data suggest a less than 5% 10-year mortality for patients treated with HAART. As a result of the reduction in early AIDS-related deaths, HIV has become a chronic disease manifesting the
Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Physicians in charge of HIV-infected patients are increasingly being faced to previously unrecognized comorbid conditions such as atherosclerosis and cardiovascular events, loss of renal function, osteopenia/osteoporosis and bone fractures or non-AIDS-defining cancers (1-4).
The incidence of these
Bococizumab HIV Evaluation (B-HIVE) Study
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Cardiovascular disease (CVD) due to atherosclerosis continues to be the leading single cause of death in industrialized countries. High serum lipid levels, and especially high low-density lipoprotein cholesterol (LDL-C) levels, have been demonstrated to strongly and directly correlate with CVD risks
Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
This is a phase IV, multicenter,, prospective, randomised, crossover, double blind, placebo-controlled and proof of concept clinical trial. The trial was conducted in a total sample of 60 patients (30 patients per group), which assures adequate power to detect differences. This study is adequate to
Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Low high density lipoprotein (HDL) and a lipid pattern consistent with atherogenic dyslipidemia are also common in the human immunodeficiency virus (HIV)infected population and is likely due, in large part, to the chronic inflammatory effect of HIV infection per se. While highly active
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The purpose of this pilot study is to compare the virological efficacy, as measured by the proportion of patients with plasma HIV-RNA below the limit of detection (<50 copies/mL), of two ARV regimens; patients are randomized to remain on regimens containing N(t)RTI(s) + PI/r or switch to Raltegravir
Raltegravir Therapy for Women With HIV and Fat Accumulation
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Abnormal liver enzymes are frequently seen in those with HIV. Although many of these individuals are co-infected with HBV or HCV, histology in HIV patients with abnormal liver enzymes in the absence of viral hepatitis has not been explored. HAART has significantly improved the survival in those
Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
Atorvastin (Lipitor) is a commonly used drug approved by the FDA for treatment of dyslipidemias. It is a relatively safe drug to use with periodic monitoring.
Eligibility critera:
- age 18-60, females, as a marjority of lupus patients are female
- at least 4 ACR (American College of Rheumatology)
Den mest komplette database med medicinske urter understøttet af videnskab
- Arbejder på 55 sprog
- Urtekurer, der understøttes af videnskab
- Urtegenkendelse ved billede
- Interaktivt GPS-kort - tag urter på stedet (kommer snart)
- Læs videnskabelige publikationer relateret til din søgning
- Søg medicinske urter efter deres virkninger
- Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning
